PETMED EXPRESS INC

PETMED EXPRESS INC Annual Report - Plain-English Breakdown for Investors
Your guide to understanding their year

---

1. What does PETMED do, and how was this year?

PETMED (ticker: PETS) operates as an online pharmacy for pets, selling medications, flea/tick treatments, and pet supplies directly to consumers. This year was challenging—sales declined as customers shifted to giants like Chewy, Amazon, or their local veterinarians. Despite offering discounts and ramping up ads, growth remained stagnant.

---

2. Financial Performance: Shrinking but Still Profitable

• Revenue: Dropped ~5% this year.
• Profits: Fell ~15% due to rising advertising and shipping costs.
• Customer Base: Fewer repeat buyers compared to last year.
• New Red Flag: Auditors found errors in 2023 and 2024 financial statements. While corrected, this raises questions about accounting reliability.

---

3. Wins & Challenges

✅ Wins:

• Launched a budget-friendly auto-ship subscription program.
• Partnered with veterinary networks to increase prescription referrals.

❌ Challenges:

• Losing customers to competitors with faster shipping and broader selection.
• Soaring digital ad costs (Google/Meta ads became 20% pricier).
• Critical Issue: Auditors flagged weak internal financial controls, meaning errors could recur without fixes.

---

4. Financial Health Check

• Cash Reserves: Healthy ($58M)—enough to cover operations for years.
• Debt: Minimal ($2M), a rare positive in today’s market.
• Dividend: Reduced slightly but still pays a 4% yield.
• New Concern: Accounting restatements and weak controls create uncertainty. Think of it like a restaurant with great food but a messy kitchen.

---

5. Risks to Watch

• Competition: Amazon and Chewy dominate with faster delivery and lower prices.
• Veterinarians: More vets now sell medications directly, bypassing PETMED.
• Regulations: Tighter rules on pet medication sales could increase costs.
• Accounting Risks: Failure to fix internal controls may lead to more errors or regulatory fines.

---

6. How They Compare to Competitors

• Chewy/Petco: Larger inventories, faster shipping, and better tech.
• Amazon: Lower prices, but PETMED offers stronger pet-specific customer service.
• Verdict: PETMED is a niche player—useful for loyal customers, but struggling to keep up.

---

7. Leadership & Strategy Shifts

• New CEO: Appointed last year, focusing on subscriptions and loyalty rewards.
• New Strategy: Pivoting from TV ads to social media and email marketing.
• Urgent Task: Leadership must rebuild trust after accounting issues.

---

8. What’s Next for PETMED?

• Aggressive discounts and promotions to regain market share.
• Testing a new app to simplify reordering.
• Make-or-Break: Fixing financial reporting systems ASAP. Auditors are watching closely.

---

9. Market Trends Impacting PETMED

• Positive: Pet spending is rising (pets are now “family members”).
• Negative: Inflation is making shoppers bargain-hunt, favoring cheaper rivals.
• Wildcard: Potential new laws requiring vet approval for more medications.

---

Bottom Line for Investors

PETMED isn’t in crisis, but it’s clearly struggling. The 4% dividend is appealing, but significant risks loom:

1. Accounting concerns demand immediate fixes to avoid fines or lost trust.
2. Competition from retail giants is relentless.
3. Customer retention is slipping—a critical metric to watch.

Treat this as a “show me” stock. If PETMED stabilizes customer losses, fixes its accounting, and leverages its debt-free balance sheet wisely, maybe it rebounds. Otherwise, it’s a risky bet in a cutthroat market.

Think of PETMED like a neighborhood hardware store competing with Home Depot. It’s still open, but you’re not sure how long it’ll last. 🐾

---

Transparency Note: PETMED’s annual report lacked depth in explaining their turnaround plans, which could signal limited transparency. Always verify updates through quarterly filings.